These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10930545)

  • 1. Preferential resistance of dopaminergic neurons to glutathione depletion in a reconstituted nigrostriatal system.
    Nakamura K; Won L; Heller A; Kang UJ
    Brain Res; 2000 Aug; 873(2):203-11. PubMed ID: 10930545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutathione depletion in nigrostriatal slice cultures: GABA loss, dopamine resistance and protection by the tetrahydrobiopterin precursor sepiapterin.
    Gramsbergen JB; Sandberg M; Møller Dall A; Kornblit B; Zimmer J
    Brain Res; 2002 May; 935(1-2):47-58. PubMed ID: 12062472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential resistance of dopaminergic neurons to the toxicity of glutathione depletion is independent of cellular glutathione peroxidase and is mediated by tetrahydrobiopterin.
    Nakamura K; Wright DA; Wiatr T; Kowlessur D; Milstien S; Lei XG; Kang UJ
    J Neurochem; 2000 Jun; 74(6):2305-14. PubMed ID: 10820190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine.
    Iwata SI; Nomoto M; Fukuda T
    Synapse; 2001 Jan; 39(1):16-22. PubMed ID: 11071705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
    Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of glutathione in dopaminergic neuronal survival.
    Nakamura K; Wang W; Kang UJ
    J Neurochem; 1997 Nov; 69(5):1850-8. PubMed ID: 9349527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.
    Morgan WW; Nelson JF
    Brain Res; 2001 Dec; 921(1-2):115-21. PubMed ID: 11720717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal dopamine output is compromised within +/- BDNF mice.
    Dluzen DE; Anderson LI; McDermott JL; Kucera J; Walro JM
    Synapse; 2002 Feb; 43(2):112-7. PubMed ID: 11754489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones.
    Wüllner U; Löschmann PA; Schulz JB; Schmid A; Dringen R; Eblen F; Turski L; Klockgether T
    Neuroreport; 1996 Mar; 7(4):921-3. PubMed ID: 8724674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor beta1 overexpression in the nigrostriatal system increases the dopaminergic deficit of MPTP mice.
    Sánchez-Capelo A; Colin P; Guibert B; Biguet NF; Mallet J
    Mol Cell Neurosci; 2003 Aug; 23(4):614-25. PubMed ID: 12932441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease.
    Crocker SJ; Wigle N; Liston P; Thompson CS; Lee CJ; Xu D; Roy S; Nicholson DW; Park DS; MacKenzie A; Korneluk RG; Robertson GS
    Eur J Neurosci; 2001 Jul; 14(2):391-400. PubMed ID: 11553289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
    McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
    J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?
    Thiruchelvam M; Brockel BJ; Richfield EK; Baggs RB; Cory-Slechta DA
    Brain Res; 2000 Aug; 873(2):225-34. PubMed ID: 10930548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice.
    Callier S; Morissette M; Grandbois M; Pélaprat D; Di Paolo T
    Synapse; 2001 Aug; 41(2):131-8. PubMed ID: 11400179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration.
    Chinta SJ; Kumar MJ; Hsu M; Rajagopalan S; Kaur D; Rane A; Nicholls DG; Choi J; Andersen JK
    J Neurosci; 2007 Dec; 27(51):13997-4006. PubMed ID: 18094238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
    Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
    J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Release of dopamine by perfusion with 1-methyl-4-phenylpyridinium ion (MPP(+)) into the striatum is associated with hydroxyl free radical generation.
    Obata T; Yamanaka Y; Kinemuchi H; Oreland L
    Brain Res; 2001 Jul; 906(1-2):170-5. PubMed ID: 11430875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
    Schmidt N; Ferger B
    Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.